EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of Tafamidis on Myocardial Function and CMR Tissue Characteristics in Transthyretin Amyloid Cardiomyopathy

Stephan Dobner iD, Benedikt Bernhard, Lorenz Ninck, Monika Wieser, Adam Bakula, Andreas Wahl, Valentin Köchli, Giancarlo Spano, Martina Boscolo Berto, Elena Elchinova, Yasaman Safarkhanlo, Stefan Stortecky und 4 weitere

ESC Heart Failure · 01.10.2024 · 11 (5) · 2759-2768

DOI: 10.1002/ehf2.14815 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 12.05.2024. Verfasst von Stephan Dobner und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Cine, Benzoxazoles, Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer AG Schweiz, GAMBIT Foundation, AstraZeneca Schweiz.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Tafamidis improves clinical outcomes in transthyretin amyloid cardiomyopathy (ATTR-CM), yet how tafamidis affects cardiac structure and function remains poorly described. This study prospectively analysed the effect of tafamidis on 12-month longitudinal changes in cardiac structure and function by cardiac magnetic resonance (CMR) compared with the natural course of disease in an untreated historic control cohort. Methods and results ATTR-CM patients underwent CMR at tafamidis initiation and at 12 months. Untreated patients with serial CMRs served as reference to compare biventricular function, global longitudinal strain (GLS), LV mass and extracellular volume fraction (ECV). Thirty-six tafamidis-treated (n = 35; 97.1% male) and 15 untreated patients (n = 14; 93.3% male) with a mean age of 78.3 ± 6.5 and 76.9 ± 6.5, respectively, and comparable baseline characteristics were included. Tafamidis was associated with preserving biventricular function (LVEF (%): 50.5 ± 12 to 50.7 ± 11.5, P = 0.87; RVEF (%): 48.2 ± 10.4 to 48.2 ± 9.4, P = 0.99) and LV-GLS (−9.6 ± 3.2 to −9.9 ± 2.4%; P = 0.595) at 12 months, while a significantly reduced RV-function (50.8 ± 7.3 to 44.2 ± 11.6%, P = 0.028; P (change over time between groups) = 0.032) and numerically worsening LVGLS (−10.9 ± 3.3 to −9.1 ± 2.9%, P = 0.097; P (change over time between groups) = 0.048) was observed without treatment. LV mass significantly declined with tafamidis (184.7 ± 47.7 to 176.5 ± 44.3 g; P = 0.011), yet remained unchanged in untreated patients (163.8 ± 47.5 to 171.2 ± 39.7 g P = 0.356, P (change over time between groups) = 0.027). Irrespective of tafamidis, ECV and native T1-mapping did not change significantly from baseline to 12-month follow-up (P > 0.05).

Conclusions

Compared with untreated ATTR-CM patients, initiation of tafamidis preserved CMR-measured biventricular function and reduced LV mass at 12 months. ECV and native T1-mapping did not change significantly comparable to baseline in both groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Magnetic Resonance Imaging, CineBenzoxazolesAmyloid Neuropathies, FamilialCardiomyopathiesHumansMaleFemaleAgedProspective StudiesVentricular Function, LeftFollow-Up StudiesStroke VolumeHeart VentriclesMyocardium

Stichwörter der Autor:innen

Cardiac amyloidosisCardiac magnetic resonance imagingECVFeature trackingGLSTafamidisTransthyretin

Substanzen

Benzoxazolestafamidis

Autor:innen und Institutionen

  • Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

ORCID-Profile: Stephan Dobner

Förderung

  • Pfizer AG Schweiz
  • GAMBIT Foundation
  • AstraZeneca Schweiz
  • Bern Amyloidosis Registry (B-CARE)

Zitieren

APA

Dobner, S., Bernhard, B., Ninck, L., Wieser, M., Bakula, A., Wahl, A., Köchli, V., Spano, G., Boscolo Berto, M., Elchinova, E., Safarkhanlo, Y., Stortecky, S., Schütze, J., Shiri, I., Hunziker, L., & Gräni, C. (2024). Impact of Tafamidis on Myocardial Function and CMR Tissue Characteristics in Transthyretin Amyloid Cardiomyopathy. ESC Heart Failure, 11(5), 2759-2768. https://doi.org/10.1002/ehf2.14815

Vancouver

Dobner S, Bernhard B, Ninck L, Wieser M, Bakula A, Wahl A, et al. Impact of Tafamidis on Myocardial Function and CMR Tissue Characteristics in Transthyretin Amyloid Cardiomyopathy. ESC Heart Failure. 2024;11(5):2759-2768. doi:10.1002/ehf2.14815

BibTeX
@article{Dobner2024,
  author = {Dobner, Stephan and Bernhard, Benedikt and Ninck, Lorenz and Wieser, Monika and Bakula, Adam and Wahl, Andreas and Köchli, Valentin and Spano, Giancarlo and Boscolo Berto, Martina and Elchinova, Elena and Safarkhanlo, Yasaman and Stortecky, Stefan and Schütze, Jonathan and Shiri, Isaac and Hunziker, Lukas and Gräni, Christoph},
  title = {Impact of Tafamidis on Myocardial Function and CMR Tissue Characteristics in Transthyretin Amyloid Cardiomyopathy},
  journal = {ESC Heart Failure},
  year = {2024},
  volume = {11},
  number = {5},
  pages = {2759--2768},
  doi = {10.1002/ehf2.14815}
}
Kostenlos starten →